HAMP and granular corneal dystrophy type II: TP-0184, a specific ALK2 inhibitor developed by Tolero Pharmaceuticals, was recently shown to block inflammatory induction of hepcidin in mouse models of ACD and cancer-induced anemia (Peterson et al., 2015).